Menu Close

Treating Neurodegeneration by Improving Autophagy

At Samsara Therapeutics, we’re on a mission to unlock the full potential of autophagy activation in combating age-related neurodegenerative diseases. Our cutting-edge research and innovative approach aim to delay the progression of these debilitating conditions, offering hope and new possibilities for patients and their families.

Our Foundation

Founded in 2019 and operating from our corporate headquarters in Boston and our R&D hub in Oxford, Samsara has emerged as a leader in the neurodegenerative disease domain. With a strong financial back of $25M from our Series A funding led by Apollo Health Ventures and further support from prestigious organizations like the ALS Association, Michael J Fox Foundation, and CMT Research Foundation, we’re poised for groundbreaking advancements.


Our senior leadership team is represented by a diverse group of seasoned experts who bring a proven track record in pharmaceutical and biotechnological innovation.

Innovative Programs Targeting Neurodegeneration

Our portfolio encompasses multiple programs, each designed to tackle various indication of neurodegenerative diseases through autophagy activation:

  • SAM001 for ALS and Parkinson’s disease (PD), leveraging lysosomal biogenesis to combat disease progression.
  • SAM0021 and SAM0022, focusing on autophagosome formation to address PD and Charcot-Marie-Tooth Disease (CMT), respectively.
  • SAM005, aiming at phagophore recruitment for CMT treatment.
  • Groundbreaking Discovery Platform: Lysoseeker®

LysoSeeker® Platform

Our proprietary screening platform, LysoSeeker®, is at the core heart of our discovery process, identifying potential autophagy activators that are then rigorously tested in our in house disease-relevant iPSC core and in various animal models through our distributed CRO network. This holistic approach enables the advancement of the most promising compounds towards clinical development.

A Future Promising Hope and Healing

As we move forward, our focus remains on translating our scientific insights into tangible treatments that can significantly impact patients’ lives. With upcoming milestones, including IND filings for our leading candidates SAM001, SAM0021, SMA0022, and SMA005, and the exploration of accelerated approval pathways, we stand at the forefront of a new era in neurodegenerative disease therapy.

Discover more about our relentless persuit of innovation and how we’re shaping the future of healthcare and Samara Therapeutics. Join us in our journey towards unlocking the mysteries of the human body and pioneering treatments for some of the most challenging diseases of our time.